Avatar of Richard A. Lange, MD, MBA

Does PPI + DAPT = MI? (16 Jul 2012)

Interventional Cardiology

Richard A. Lange, MD, MBA and L. David Hillis, MD

Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is the standard of care for prevention of coronary stent thrombosis. Unfortunately, DAPT is associated with an increased risk for gastrointestinal hemorrhage. Although this risk can be reduced with the concomitant administration of a proton pump inhibitor (PPI), initial observational studies suggested that PPI use with DAPT is associated with an increased…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Genetic and Clinical Factors Linked to Stent Thrombosis (25 Oct 2011)

News

French researchers have identified several genetic and clinical factors independently tied to early stent thrombosis. Writing in the Journal of the American Medical Association, Guillaume Cayla and colleagues report on their case-control study comparing 123 patients with definite early stent thrombosis with 246 matched controls without stent thrombosis. The researchers found three genes with variants…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Updated Unstable Angina/Non-STEMI Guidelines Released by ACC & AHA (28 Mar 2011)

News

The AHA and ACC have released a focused update of the 2007 guidelines for the management of unstable angina and non-STEMI. The guidelines incorporate new information from recent clinical trials, and deal with controversial topics such as the choice of antiplatelet agents, the use of platelet-function and genetic tests with antiplatelet agents, and the timing…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Statement from AHA, ACC, and ACG Reaffirms Use of PPIs with Antiplatelet Therapy (9 Nov 2010)

News

Despite recent warnings by the FDA, an expert consensus document released jointly by the AHA, the ACC, and the American College of Gastroenterology states that it is acceptable to use proton pump inhibitors (PPIs) with thienopyridines like clopidogrel in patients at high risk for upper GI bleeds. The statement does not recommend routine use of…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Encouraging Observational Data on Clopidogrel and PPIs (20 Sep 2010)

News

Compared with a PPI alone, the combination of clopidogrel and a PPI does not increase risk for cardiovascular events, according to a large observational study from Denmark published in the Annals of Internal Medicine. Mette Charlot and colleagues analyzed data from 56,406 Danish patients discharged after a first MI and found no difference between the…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.